Translational Lung Cancer Research

Article	Citations
Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors	65
Evaluation of gut leakage and bacterial translocation as efficacy biomarkers of immunotherapy in advanced non-small cell lung cancer (NSCLC)	57
Comparison of efficacy and surgery-related safety of perioperative tislelizumab and pembrolizumab with neoadjuvant chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study	47
The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–2030	42
Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report	42
Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China	37
Molecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes	33
DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling	31
Contrast-enhanced CT and PET-CT characteristics of primary tracheal lymphoepithelioma-like carcinoma: case series	31
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer	30
Metachronous development of L858R and T790M EGFR mutations following ALK inhibitor therapy in stage IV lung adenocarcinoma: a case report	28
Prognostic factors of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor (TKI): a nationwide registry study in China	28
Density and maturity ratio of tertiary lymphoid structures in stage II–III non-small cell lung cancer predict postoperative recurrence risk	28
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer	28
Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer	27
PFKP confers chemoresistance by upregulating ABCC2 transporter in non-small cell lung cancer	26
Microbiota modulate lung squamous cell carcinoma lymph node metastasis through microbiota-geneset correlation network	26
Whole genome characterization of patient-derived lung cancer organoids	26
Targeting ferroptosis to overcome drug resistance in lung cancer	26
Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression	25
Change of bone mineral density as a prognostic marker in small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study	25
Optimizing long-term treatment with ALK inhibitors: balancing efficacy and safety	25
Real-world data on severe lung cancer: a multicenter retrospective study	25
Predictive value of perioperative carcinoembryonic antigen changes for recurrence in non-small cell lung cancer	25
A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA	24

Diagnostic accuracy and safety of electromagnetic navigation transthoracic needle biopsy under moderate sedation for the diagnosis of peripheral pulmonary lesions	23
Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?	23
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer	23
DNA methylation profiling in early lung adenocarcinoma to predict response to immunotherapy	22
Survival outcomes and risk factors after lung transplantation in patients with pre-transplant malignancy: a national cohort study	21
Sacituzumab govitecan: a new hope for patients with pretreated extensive small-cell lung cancer (SCLC)—insights from the TROPiCS-03 trial	21
PD-L1 expression as a prognostic factor for postoperative outcomes in pleural mesothelioma	21
The opportunities and challenges of perioperative therapy of localized non-small cell lung cancer—thoughts from the KEYNOTE-671 trial	20
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with con	20
Tackling a caveat of the FLAURA trial and building solid evidence for frail patients in thoracic oncology	20
Causal effects of genetically determined metabolites on cancers included lung, breast, ovarian cancer, and glioma: a Mendelian randomization study	20
Dynamic change of CD8+ T cell: immunotherapy fate tell?	20
KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer	20
Integrative modeling of longitudinal cell-free DNA and tumor volume dynamics: a multimodal quantitative prognostic framework	20
Prognostic factors affecting mortality in elderly, low body mass index, and poor performance status groups with lung cancer: analysis of the 2016 Korean Association of Lung Cancer Registry (KALC-R) da	20
The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer	19
Needle tract seeding after endobronchial ultrasound-guided intranodal forceps biopsy and cryobiopsy: a case report	19
Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study	18
Development of an AI model for predicting hypoxia status and prognosis in non-small cell lung cancer using multi-modal data	18
Neoadjuvant immunochemotherapy in potentially resectable small cell lung cancer: a real-world retrospective analysis	18
Can circulating tumor DNA guide treatment de-escalation in metastatic lung adenocarcinoma harboring actionable genomic alterations?	18
Impact of baseline brain metastases on survival and CNS progression in NSCLC patients treated with immune checkpoint inhibitors in real-world studies: a systematic review and meta-analysis	18
Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?	18
Hyperthermic intrathoracic chemotherapy in overcoming tyrosine kinase inhibitor resistance in a patient with malignant pleural effusion: a case report	18
Some like it hot: the potential role of hyperthermic intrathoracic chemotherapy in the multimodality treatment of pleural mesothelioma	17
Comparative survival outcomes between EGFR-wildtype and EGFR-mutant lung adenocarcinoma following neoadjuvant chemoimmunotherapy: a retrospective cohort study from national cancer center in China	17
Connecting the dots: (RANKL+) extracellular vesicle count in blood plasma in relation to bone metastases, skeletal related events and osimertinib treatment in patients with EGFR mutated non-small cell	17
Advancements of ALK inhibition of non-small cell lung cancer: a literature review	16
Tarlatamab: the promising immunotherapy on its way from the lab to the clinic	16
Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study	16
Treatment patterns and clinical outcomes of resectable central non-small cell lung cancer patients undergoing sleeve lobectomy: a large-scale, single-center, real-world study	16
Identification of distinct tumor cell patterns with single-cell RNA sequencing integrating primary lung adenocarcinoma and brain metastasis tumor	15
Follow-up regimen after lung cancer treatment: about the how and why	15
Another point of view for meta-analysis studies focused on protective inhaled corticosteroids and the risk of lung cancer	15
Single-cell and spatial transcriptomics reveal a potential role of ATF3 in brain metastasis of lung adenocarcinoma	15
Potential efficacy of anti-angiogenic therapy combined with immunotherapy for advanced SMARCA4-deficient thoracic tumor: a retrospective study	15
Homologous recombination pathway gene variants identified by tumor-only sequencing assays in lung carcinoma patients	15
LungPath: artificial intelligence-driven histologic pattern recognition for improved diagnosis of early-stage invasive lung adenocarcinoma	15
Navigating treatment sequencing in ALK-positive non-small cell lung cancer: lorlatinib as a key to prolonged survival?	15
Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer	15
Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18	15
Discrepancies in PD-L1 expression, lymphocyte infiltration, and tumor mutational burden in non-small cell lung cancer and matched brain metastases	15
Maintenance therapy for metastatic non-squamous non-small cell lung cancer: efficacy and biomarker analysis of pemetrexed discontinuation	15
International cost-effectiveness analysis of durvalumab consolidation treatment after chemoradiotherapy for patients with limited-stage small-cell lung cancer	14
Pulmonary ground glass opacity tumor: a curable subtype of lung cancer when treated within the “surgical curative time window”	14
Expression of YAP1 delineates distinct subtypes of pulmonary large cell neuroendocrine carcinoma with divergent therapeutic implications	14
Mid-term efficacy and safety of transbronchial cryoablation for stage IA peripheral lung cancer: a retrospective analysis	14
Spontaneous ventilation video-assisted thoracoscopic surgery for octogenarian non-small cell lung cancer patients: a non-inferiority study	14
Association between patient-reported outcomes and pathological response in neoadjuvant chemoimmunotherapy—a post hoc analysis of the TD-FOREKNOW trial	14
Health-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases	14

Treatment interruption during neoadjuvant immuno-chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials	13
Development and validation of a dynamic survival nomogram for metastatic non-small cell lung cancer based on the SEER database and an external validation cohort	13
Completion lobectomy following segmentectomy for malignant lung tumors: a multi-institutional study of surgical feasibility, oncologic outcomes, and diagnostic challenges (ESSG-02 study)	13
A case series of nonintubated robotic-assisted bronchoscopy: a feasible alternative to intubated techniques	13
Stage- and smoking-associated microRNA expression in lung adenocarcinoma	13
Lightweight hybrid foundation model for lung cancer prognosis based on low-dose chest X-ray images	13
Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study	13
Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 ≥50%	13
Will “Sun”-WUKONG, the monkey king, conquer EGFR exon 20 insertion mutation positive non-small cell lung cancer?	13
Enhancing the sensitivity of lung adenocarcinoma to immune therapeutic agents through SPRED1	13
Advances in the research on radiotherapy for lung cancer: a 2025 review	13
Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review	13
One-year mortality risk prediction model for patients with interstitial lung disease and lung cancer	13
Preclinical evaluation of thin convex probe endobronchial ultrasound-guided transbronchial needle aspiration for intrapulmonary lesions	12
The impact of neoadjuvant chemoimmunotherapy on pulmonary function in non-small cell lung cancer patients	12
Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions	12
Evaluating three-dimensional lung reconstructions for thoracoscopic lung resections using open-source software: a pilot study	12
Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review	12
Exploration of a novel prognostic model based on nomogram in non-small cell lung cancer patients with distant organ metastasis: implications for immunotherapy	12
Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC	12
Lower respiratory tract microbiome is associated with checkpoint inhibitor pneumonitis in lung cancer patients	12
Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study	12
Patient-reported impact of symptoms in lung cancer (PRISM-LC)	12
DLL3-targeted CAR T-cell therapy in pre-clinical models for small cell lung cancer: safety, efficacy, and challenges	12
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study	12
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged N	11
Cancer cachexia research: coming of age	11
Dual immuno-oncology agents as neoadjuvant therapy for patients with resectable non-small cell lung cancer	11
Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple ALK fusions treated with tyrosine kinase inhibitors	11
Outcomes and prognostic insights in primary tracheal cancer: a multicenter retrospective study	11
Clinical and prognostic significance of detecting CEA, EGFR, LunX, c-met and EpCAM mRNA-positive cells in the peripheral blood, tumor-draining blood and bone marrow of non-small cell lung cancer patie	11
Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer	11
PD-1 expression on tumor cells: a new target for cancer therapy	11
Paving the way for ctDNA-guided trials in lung cancer: insights from the LIBELULE study	11
Lung cancer susceptibility beyond smoking history: opportunities and challenges	11
Radiotherapy as salvage therapy and an adjunct to immunotherapy: exploring local and abscopal mechanisms to overcome immunotherapy resistance: a narrative review	11
Subtype-specific RNA sequencing using micro-dissection revealed extracellular matrix alterations as key factors in lung adenocarcinoma invasion	11
Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study	11
Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer	11
Association of cholesterol and triglyceride levels with the recurrence of early-stage lung adenocarcinoma with micropapillary pattern	11
Development and validation of an interpretable machine learning model for prediction of occult lymph node metastasis in clinical stage T1 lung adenocarcinoma	11
Mechanistic insights into the immune biomarker of perioperative immune checkpoint inhibitors for non-small cell lung cancer	11
Immune-related osteoblastic bone alterations mimicking bone metastasis in a small-cell lung cancer patient treated with durvalumab: a case report	10
Macrophages in lung cancer: principal factors, regulatory mechanisms, and therapeutic opportunities: a narrative review	10
Real-time breath metabolomics as catalyst for personalized lung cancer diagnostics: prospective matched case-control trial (LUCAbreath)	10
Exploring the efficacy of artificial neural networks in predicting lung cancer recurrence: a retrospective study based on patient records	10
Enhancing the precision of auxiliary diagnosis for lung cancer through use of SHOX2 and RASSF1A methylation status in lung biopsy and lymph node biopsy specimens	10
Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB–IIIA non-small cell lung cancer	10
Future lung cancer prediction using low-dose chest computed tomography	10
Integrating deep learning and radiomics in the differentiation of major histological subtypes of invasive non-mucinous lung adenocarcinoma using positron emission tomography and computed tomography	10
Targeted therapy for stage IA non-small cell lung cancer with EGFR mutations: a scoping review	9
Remarkable response to personalized combination immunotherapy of nivolumab plus ipilimumab in an 84-year-old patient with locally advanced squamous cell carcinoma: a case report	9
SMARCA4 deficiency: implications for non-small cell lung cancer and management strategies, with relevance to and distinctions from thoracic undifferentiated tumor	9
Natural course of lung adenocarcinoma manifesting as ground-glass nodules: invasiveness assessment based on growth evaluation	9
Epidermal growth factor receptor exon 20 insertion mutations: are we getting closer to solving the puzzle?	9
Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers	9
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study	9
A prospective phase 2 study of expeditious EGFR genotyping and immediate therapeutic initiation through extracellular vesicles (EV)-based bronchoalveolar lavage fluid (BALF) liquid biopsy in advanced	9
Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally ad	9
From tradition to transformation: evolving paradigms in surgical lung cancer treatment	9
NOTCH4 as a driver of epithelial-mesenchymal transition, angiogenesis, and stromal remodeling in lung adenocarcinoma: integrated transcriptomic and protein-level validation	9
3D computed tomography airway geometry for predicting bronchoscopic accessibility in peripheral pulmonary nodules: a prospective study	9
Predictive value of the monocyte-to-high-density lipoprotein ratio in the prognosis of non-small cell lung cancer patients after surgery	9
A comprehensive clinical trajectory of EGFR A763_Y764insFQEA-positive non-small cell lung cancer treated with fifth-line osimertinib following circulating tumor DNA-based detection: a case report	9
Exosomal miR-182-5p is a potential diagnostic marker for malignant pleural effusion	9
First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic	9
Cellular senescence and lung cancer prognosis	9
Identification of lysosomal genes associated with prognosis in lung adenocarcinoma	9
Lymph node dissection of station 8 improves the survival of T≤3 cmN0M0 lung adenocarcinoma patients	9
Utility of ctDNA-molecular residual disease in predicting minimal residual disease in non-small cell lung cancer patients after radical resection	8
Racial disparities in histological subtype, stage, tumor grade and cancer-specific survival in lung cancer	8
Fibre-based fluorescence-lifetime imaging microscopy: a real-time biopsy guidance tool for suspected lung cancer	8
Higher proximity of PD-L1+ tumor cells to PD-1+ tissue-resident memory CD8 determines response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer	8
False positivity in break apart fluorescence in-situ hybridization due to polyploidy	8
The OPEN trial—from the darkness, comes light	8
Fluorofenidone enhances cisplatin efficacy in non-small cell lung cancer: a novel approach to inhibiting cancer progression	8
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancer	8
A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab	8
Circulating tumor DNA as prognostic markers of non-small cell lung cancer (NSCLC): a systematic review and meta-analysis	8
Efficacy and safety of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in patients with extensive-stage small-cell lung cancer: a retrospective cohort study	8

Oncogene-addicted solid tumors and microbiome—lung cancer as a main character: a narrative review	8
Age at first sexual intercourse, age at menarche, and age at menopause: a mendelian randomization study on lung cancer risk	8
What do we know about the role of neoadjuvant targeted therapy in early-stage EGFR-mutant and ALK-fused non-small cell lung cancer?—a narrative review of the current literature	8
The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy: a retrospective study	8
Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboring HER2 exon 19, p.L755P mutation: case report	8
Predictive value of longitudinal systemic inflammatory markers for pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer	8
Integrating radiomics and deep learning for enhanced prediction of high-grade patterns in stage IA lung adenocarcinoma	8
Is seeing believing?—signal differentiation in a preclinical transbronchial imaging study implementing a composite optical fiber bronchoscope to detect a folate receptor-targeted near-infrared fluorop	8
Penetrating the central nervous system sanctuary of KRAS, a target once thought “undruggable”	8
Metabolite biomarkers in lung cancer: unlocking the potential of body fluid analysis for early detection and prognosis—a narrative review	8
Radiomic phenotypes of oligometastatic non-small cell lung cancer	8
Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: a narrative review	8
Construction and validation of deep learning model for cachexia in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors: a multicenter study	8
Learning curve for uniportal thoracoscopic pulmonary segmentectomy: how many procedures are required to acquire expertise?	8
Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancer	8
Comparative efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy versus combined EGFR-TKI and chemotherapy in resectable EGFR-mutant non-small cell lung cancer	8
Reducing radiation pneumonitis in lung cancer patients: from Chinese expert consensus to practice	8
Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients	8
Good responses to first-line immunotherapy-included treatment in lung squamous carcinoma with rare driver gene mutations: a report of three cases	8
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer	8
Knowledge and beliefs about lung cancer screening among Black individuals at high risk: a qualitative approach	8
Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence	8
Prognostic analysis and beneficiary population exploration of subsequent treatment regimens after third-generation EGFR-TKIs failure in EGFR-mutated advanced non-small cell lung cancer: a retrospectiv	7
Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated n	7
Increased serum levels of KiSS1-derived peptides in non-small cell lung cancer patient liquid biopsies and biological relevance	7
Altered carnitine transporter genes (SLC22A5, SLC22A16, SLC6A14) expression pattern among lung cancer patients	7
Comparative analysis of lung cancer risk factors between never-smokers and heavy smokers: a nationwide population-based study in Korea	7
Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer	7
Impact of lymph node dissection on cancer-specific survival in non-small cell lung cancer patients: a SEER database analysis	7
Pneumonectomy—a necessary evil?	7
Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer	7
Determinants of Aurora kinase B inhibitor sensitivity in small cell lung cancer	7
Integrative genomic profiling reveals characteristics of lymph node metastasis in small cell lung cancer	7
Neoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review	7
Investigation of non-completion factors for durvalumab maintenance therapy in locally advanced non-small cell lung cancer	7
Current advances in extended resections for non-small cell lung cancer—a narrative review	7
Cerebrospinal fluid cytology for the diagnosis of lung cancer brain metastasis: a case report	7
Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer	7
Osimertinib as a neoadjuvant therapy in resectable EGFR-mutant non-small cell lung cancer: a real-world, multicenter retrospective study	7
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22	7
Comprehensive management of MET tyrosine kinase inhibitor-induced peripheral edema in patients with MET-altered non-small-cell lung cancer: a narrative review	7
Safety and efficacy of transbronchial radiofrequency ablation for stage IA peripheral lung cancer: a retrospective cohort study	7
Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)	7
Biomarkers as a tool to reduce disparities in lung cancer screening and detection	7
Systemic immune index predicts tumor-infiltrating lymphocyte intensity and immunotherapy response in small cell lung cancer	7
Residual tumor descriptors proposed by the International Association for the Study of Lung Cancer may not be applicable to stage I and ground-glass opacity-featured non-small cell lung cancer	7
A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma	7
Local consolidative therapy for the primary tumor in EGFR-mutant advanced non-small cell lung cancer following osimertinib plus chemotherapy: a protocol for a single-arm, open-label, phase 2 trial	7
Consolidation thoracic radiotherapy following quadruple induction with benmelstobart, anlotinib, and chemotherapy for extensive-stage small cell lung cancer: rationale and protocol of a phase II study	7
DeepGR: a deep-learning prognostic model based on glycolytic radiomics for non-small cell lung cancer	7
Extending the clinical indications of liquid biopsy: plasma next-generation sequencing in suspected lung cancer	7
BRAF RNA is prognostic and widely expressed in lung adenocarcinoma	7
Efficacy of neoadjuvant immunochemotherapy in the treatment of stage III non-small-cell lung cancer with cancer driver gene mutations	7
Differential impact of intratumor heterogeneity (ITH) on survival outcomes in early-stage lung squamous and adenocarcinoma based on tumor mutational burden (TMB)	7
The IASLC grading system as a predictor for EGFR-TKI therapy in patients with EGFR-mutant lung adenocarcinoma	7
The APPLE trial in the evolving landscape of ctDNA monitoring	7
Invasive mucinous adenocarcinoma harbored MET exon 14 skipping mutation: case report	7
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review	7
Prognostic implications of MDM2 expression in surgically resected epidermal growth factor receptor mutant lung cancer with pathological lymph node metastasis	7
Radiotherapy vs. photodynamic therapy: a comparison of antitumor effects and pulmonary toxicity in preclinical models	7
Multidisciplinary international expert consensus on perioperative airway management	7
STING facilitates the development of radiation-induced lung injury via regulating the PERK/eIF2α pathway	7
Primary resistance to ALK inhibitors in KLC1/ALK-rearranged pleural metastatic lung adenocarcinoma: a case report	6
Contribution of crosstalk of mesothelial and tumoral epithelial cells in pleural metastasis of lung cancer	6
Comparative study of bronchoscopic and CT-guided percutaneous microwave ablation for inoperable non-small cell lung cancer	6
Genomic alterations dissection revealed MUC4 mutation as a potential driver in lung adenocarcinoma local recurrence	6
Targeting heterogeneity in atypical epidermal growth factor receptor-mutated non-small cell lung cancer: insights from CHRYSALIS-2	6
The time-to-surgery interval and its effect on pathological response after neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a retrospective cohort study	6
Development of a cuproptosis-related signature for prognosis prediction in lung adenocarcinoma based on WGCNA	6
Clinical application of three-dimensional reconstruction in anatomical analysis of the right anterior, lateral, and posterior basal segments (RS8, RS9, and RS10) for RS9 segmentectomy	6
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study	6
Incremental prognostic value of solid component volume ratio and entropy for pathological stage IA invasive lung adenocarcinoma after surgery	6
PKC-iota drives EGFR-TKI resistance in EGFR-mutated NSCLC by phosphorylating FASN to reprogram lipid metabolism	6
Predicting survival in small cell lung cancer patients undergoing various treatments: a machine learning approach	6
A radiomics nomogram integrated with radiological features for preoperative prediction of lung nodule invasiveness: comparison with Lung-RADS	6
KMT2C expression and DNA homologous recombination repair factors in lung cancers with a high-grade fetal adenocarcinoma component	6
Patient-focused insights: how emotional distress shapes immunotherapy response in non-small cell lung cancer	6
A potential central nervous system niche for trastuzumab deruxtecan in patients with HER2-expressing non-small cell lung cancer	6
A narrative review from gut to lungs: non-small cell lung cancer and the gastrointestinal microbiome	6
Ion robotic bronchoscopy laser ablation and Da Vinci robotic segmentectomy for bilateral pulmonary nodules: a case report	6
Value of 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the differential diagnosis of sarcoidosis and lung cancer with lymph node metastasis: a retrospectiv	6
A CT imaging-based deep learning model for predicting EGFR and KRAS mutations in non-small cell lung cancer: toward personalized treatment approaches	6
Molecular and immune characterization of Chinese early-stage non-squamous non-small cell lung cancer: a multi-omics cohort study	6
Electromagnetic navigation bronchoscopy for localization of bilateral multiple pulmonary nodules: a comparative evaluation of safety and efficacy	6
Fructose-diphosphate aldolase C as a novel diagnostic biomarker for early-stage non-small cell lung cancer: a low-abundance proteomics study	6
Association of systemic therapy with survival among adults with advanced non-small cell lung cancer	6
Review of the use of radiomics to assess the risk of recurrence in early-stage non-small cell lung cancer	6
EGFR inhibitors plus dabrafenib and trametinib in patients with EGFR-mutant lung cancer and resistance mediated by BRAFV600E mutation: a multi-center real-world experience in China	6
Neoadjuvant chemo-immunotherapy in a kidney transplant recipient with locally advanced non-small cell lung cancer: a case report of a therapeutic dilemma	6
International expert consensus on immunotherapy for early-stage non-small cell lung cancer	6
Evaluation of the novel International Association for the Study of Lung Cancer grading system in adenocarcinoma with spread through air space	6
Pulmonary ground-glass opacity associated with cystic airspace: clinicopathological features and aggressiveness	6
Shift in lung cancer stage at diagnosis during the COVID-19 pandemic in New York City	6
Prognostic impact of negative TTF-1 biomarker in metastatic lung adenocarcinoma treated with chemo-immunotherapy: a retrospective cohort study	6
Effect of cold ischemia time and storage temperature on anaplastic lymphoma kinase (ALK) expression in surgically resected lung cancer specimens	6